Statement of Comprehensive Income

Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

Pfizer Inc., consolidated statement of comprehensive income

US$ in millions

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income before allocation to noncontrolling interests	8,062)	2,158)	31,407)	22,025)	9,652)
Foreign currency translation adjustments, net	(124)	485)	(2,204)	(725)	1,036)
Reclassification adjustments	—)	—)	—)	—)	(17)
Foreign currency translation adjustments	(124)	485)	(2,204)	(725)	1,019)
Unrealized holding gains (losses) on derivative financial instruments, net	403)	514)	1,261)	442)	(494)
Reclassification adjustments for (gains) losses included in net income	(130)	(320)	(1,792)	105)	46)
Derivative financial instruments	273)	194)	(531)	547)	(448)
Unrealized holding gains (losses) on available-for-sale securities, net	(133)	(106)	(1,142)	(311)	316)
Reclassification adjustments for (gains) losses included in net income	37)	(123)	1,583)	(26)	(164)
Available-for-sale securities	(96)	(229)	441)	(337)	152)
Actuarial gains (losses), net	—)	—)	—)	—)	(847)
Reclassification adjustments related to amortization	—)	—)	—)	—)	214)
Reclassification adjustments related to settlements, net	—)	—)	—)	—)	213)
Other	—)	—)	—)	—)	(183)
Actuarial gains (losses)	—)	—)	—)	—)	(603)
Prior service (costs) credits and other, net	148)	(20)	(19)	89)	40)
Reclassification adjustments related to amortization of prior service costs and other, net	(83)	(89)	(100)	(107)	(145)
Reclassification adjustments related to curtailments of prior service costs and other, net	(2)	(11)	(9)	(57)	—)
Other	—)	—)	—)	—)	(1)
Prior service (costs) credits and other	63)	(120)	(128)	(75)	(106)
Benefit plans	63)	(120)	(128)	(75)	(709)
Other comprehensive income (loss) before allocation to noncontrolling interests	116)	330)	(2,422)	(590)	14)
Comprehensive income before allocation to noncontrolling interests	8,178)	2,488)	28,985)	21,435)	9,666)
Comprehensive income attributable to noncontrolling interests	(29)	(26)	(20)	(42)	(27)
Comprehensive income attributable to Pfizer Inc.	8,149)	2,462)	28,965)	21,393)	9,639)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Comprehensive income item	Description	The company
Net income attributable to Pfizer Inc. common shareholders	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Pfizer Inc. net income attributable to Pfizer Inc. common shareholders decreased from 2022 to 2023 but then slightly increased from 2023 to 2024.
Comprehensive income attributable to Pfizer Inc.	Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners.	Pfizer Inc. comprehensive income attributable to Pfizer Inc. decreased from 2022 to 2023 but then slightly increased from 2023 to 2024.

Pfizer Inc. (NYSE:PFE)

Statement of Comprehensive Income